11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – peginterferon beta-1a

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Peginterferon beta-1a

Peginterferon beta-1a

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. EMA. Plegidry. Assessment Report 2014-05-22. https://goo.gl/3V51Y6

  2. FDA. Plegidry. Clinical Pharmacology and Biopharmaceutics Review 2013-05-15. https://goo.gl/QDJ0u3

  3. Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM, Albano JD, Rametta MJ. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4:e004536.

  4. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17:423-30.

  5. Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005;65:802-6.

  6. Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016;22:801-9.

  1. EMA. Plegidry. Assessment Report 2014-05-22. https://goo.gl/3V51Y6
  2. FDA. Plegidry. Clinical Pharmacology and Biopharmaceutics Review 2013-05-15. https://goo.gl/QDJ0u3
  3. Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM, Albano JD, Rametta MJ. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4:e004536.
  4. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17:423-30.
  5. Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005;65:802-6.
  6. Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016;22:801-9.